MARCUS JOEL S

SEC source: 0001193125-26-420734 · ownership.xml · derivative · entry 2

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 41,871 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: On October 13, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 3.8649-to-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · derivative.exercise_date: On October 13, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 3.8649-to-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.

F1 · derivative.expiration_date: On October 13, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 3.8649-to-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.

SEC source: 0001193125-26-420734 · ownership.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,871

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: On October 13, 2026, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 3.8649-to-1 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The shares have no expiration date.

SEC source: 0001193125-26-418302 · ownership.xml · derivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 17,500 shares

Expires 2036-10-08

F1 · derivative.exercise_date: The option vests in full on October 8, 2027, subject to the reporting person's continued service through such date.

SEC source: 0001216955-26-000021 · wk-form4_1789505061.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 597,724

F1 · price: The shares were purchased at prices ranging from $49.38 to $49.82. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001216955-26-000019 · wk-form4_1787171829.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 592,724

F1 · price: The shares were purchased at prices ranging from $46.12 to $46.50. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001216955-26-000017 · wk-form4_1778185919.xml · nonDerivative · entry 2

MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 587,724

F2 · price: The shares were purchased at prices ranging from $46.44 to $46.96. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001216955-26-000017 · wk-form4_1778185919.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 584,213

F1 · price: The shares were purchased at prices ranging from $45.34 to $46.30. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001216955-26-000015 · wk-form4_1778100512.xml · nonDerivative · entry 3

MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 580,224

F3 · price: The shares were purchased at prices ranging from $43.41 to $43.97. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001216955-26-000015 · wk-form4_1778100512.xml · nonDerivative · entry 2

MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 578,618

F2 · price: The shares were purchased at prices ranging from $42.38 to $43.35. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001216955-26-000015 · wk-form4_1778100512.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 574,786

F1 · price: The shares were purchased at prices ranging from $41.36 to $42.36. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001216955-26-000013 · wk-form4_1778013158.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 572,724

F1 · price: The shares were purchased at prices ranging from $40.64 to $41.58. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001216955-26-000011 · wk-form4_1771019097.xml · nonDerivative · entry 2

MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 562,724

F2 · price: The shares were purchased at prices ranging from $54.02 to $54.65. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001216955-26-000011 · wk-form4_1771019097.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 555,024

F1 · price: The shares were purchased at prices ranging from $53.49 to $53.97. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price.

SEC source: 0001216955-26-000009 · wk-form4_1769471114.xml · nonDerivative · entry 2

MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 537,724

F1 · shares: Represents the forfeiture of a portion of a restricted stock award previously reported.

SEC source: 0001216955-26-000009 · wk-form4_1769471114.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 572,799

F1 · shares: Represents the forfeiture of a portion of a restricted stock award previously reported.

SEC source: 0001216955-26-000007 · wk-form4_1768340600.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 587,470

SEC source: 0001216955-26-000003 · wk-form4_1767660111.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 487,414

SEC source: 0000950170-25-049596 · ownership.xml · derivative · entry 4

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,951 shares

Expires not disclosed

F6 · derivative.exercise_price: Each restricted stock unit (each, a "Company RSU") represented a contingent right to re-ceive one Company Share.

F7 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances.

F7 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggre-gate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances.

F8 · derivative.expiration_date: Not applicable.

SEC source: 0000950170-25-049596 · ownership.xml · derivative · entry 3

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,322 shares

Expires 2034-06-13

F4 · price: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F5 · price: (Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration.

F4 · derivative.exercise_date: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F5 · derivative.exercise_date: (Continued from Footnote 4) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Considera-tion was canceled for no consideration.

SEC source: 0000950170-25-049596 · ownership.xml · nonDerivative · entry 2

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time").

F2 · kind: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time").

F2 · price: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings.

F3 · ownership.nature: Represents securities held of record by Alexandria Real Estate Equities, Inc. The reporting person is the Executive Chairman & Founder of Alexandria Real Estate Equities, Inc. and may therefore be deemed to have voting and investment power with respect to the shares owned by Alexandria Real Estate Equities, Inc. The reporting person disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.

SEC source: 0000950170-25-049596 · ownership.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time").

F2 · kind: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings.

F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and condi-tions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time").

F2 · price: (Continued from Footnote 1) At the Effective Time, each share of common stock, par val-ue $0.0001 per share, of the Company ("Company Shares") issued and outstanding im-mediately prior to the Effective Time (other than certain Company Shares canceled pur-suant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings.

SEC source: 0000950170-25-028030 · ownership.xml · derivative · entry 3

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,009 shares

Expires 2033-06-22

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: All shares underlying this option have vested.

SEC source: 0000950170-25-028030 · ownership.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 48,238

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001035443-25-000037 · wk-form4_1736890656.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 456,144

SEC source: 0001035443-25-000018 · wk-form4_1735941092.xml · nonDerivative · entry 2

MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 409,937

SEC source: 0001035443-25-000018 · wk-form4_1735941092.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 394,327

F1 · shares: Represents the forfeiture of a portion of a restricted stock award previously reported.

SEC source: 0000950170-24-077469 · ownership.xml · derivative · entry 3

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,567 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock.

F3 · derivative.exercise_date: On June 23, 2023, the reporting person was granted 1,567 restricted stock units, which vested on the first anniversary of the grant date (June 23, 2024).

F3 · derivative.expiration_date: On June 23, 2023, the reporting person was granted 1,567 restricted stock units, which vested on the first anniversary of the grant date (June 23, 2024).

SEC source: 0000950170-24-077469 · ownership.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,229

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock.

SEC source: 0000950170-24-075079 · ownership.xml · derivative · entry 2

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,322

Underlying: Common Stock · 4,322 shares

Expires 2034-06-13

SEC source: 0000950170-24-075079 · ownership.xml · derivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,951

Underlying: Common Stock · 2,951 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock.

F2 · derivative.exercise_date: On June 14, 2024, the reporting person was granted 2,951 restricted stock units, vesting on the first anniversary of the grant date (June 14, 2025).

F2 · derivative.expiration_date: On June 14, 2024, the reporting person was granted 2,951 restricted stock units, vesting on the first anniversary of the grant date (June 14, 2025).

SEC source: 0000950170-24-070634 · ownership.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 498,414

F1 · shares: Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One-fourth (1/4th) of the Restricted Stock Units shall vest on a quarterly basis from June 6, 2024 until the earlier of (i) the first anniversary of the date of grant and (ii) the date of the issuer's next annual stockholder meeting, in each case, subject to the reporting person's continuous service as of each such date.

SEC source: 0001035443-24-000119 · wk-form4_1712090852.xml · nonDerivative · entry 2

MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 413,483

F2 · shares: Represents shares withheld by the issuer to satisfy a tax obligation realized by the reporting person upon the vesting of restricted stock.

SEC source: 0001035443-24-000119 · wk-form4_1712090852.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 418,883

F1 · shares: Represents the forfeiture of a portion of a restricted stock award previously reported.

SEC source: 0000950170-24-021563 · ownership.xml · derivative · entry 8

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,757 shares

Expires 2032-06-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: All shares underlying this option have vested.

SEC source: 0000950170-24-021563 · ownership.xml · derivative · entry 7

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,000 shares

Expires 2031-06-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: All shares underlying this option have vested.

SEC source: 0000950170-24-021563 · ownership.xml · nonDerivative · entry 5

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,662

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.53 to $69.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0000950170-24-021563 · ownership.xml · nonDerivative · entry 4

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,961

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.53 to $69.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0000950170-24-021563 · ownership.xml · nonDerivative · entry 3

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,619

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.53 to $68.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0000950170-24-021563 · ownership.xml · nonDerivative · entry 2

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,990

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-021563 · ownership.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,233

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001035443-24-000079 · wk-form4_1709155889.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 429,538

SEC source: 0001035443-24-000046 · wk-form4_1705094747.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 437,038

SEC source: 0001035443-24-000043 · wk-form4_1704837862.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 401,974

SEC source: 0001035443-24-000026 · wk-form4_1704405282.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 398,974

SEC source: 0001209191-23-050097 · doc4.xml · derivative · entry 2

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,375 shares

Expires 2032-06-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: These options are fully vested.

SEC source: 0001209191-23-050097 · doc4.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 453,414

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-23-039927 · doc4.xml · derivative · entry 2

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,009

Underlying: Common Stock · 7,009 shares

Expires 2033-06-22

SEC source: 0001209191-23-039927 · doc4.xml · derivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,567

Underlying: Common Stock · 1,567 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock.

F2 · derivative.exercise_date: On June 23, 2023, the reporting person was granted 1,567 restricted stock units, vesting on the first anniversary of the grant date (June 23, 2024).

F2 · derivative.expiration_date: On June 23, 2023, the reporting person was granted 1,567 restricted stock units, vesting on the first anniversary of the grant date (June 23, 2024).

SEC source: 0001209191-23-035599 · doc4.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 441,039

F1 · shares: Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One-fourth (1/4th) of the Restricted Stock Units shall vest on each of September 6, 2023, December 6, 2023, March 6, 2024 and the date which is the earlier of June 6, 2024 and the 2024 annual stockholder meeting, subject to the Reporting Person continuing to provide services through each such date.

SEC source: 0001035443-23-000205 · wf-form4_168375093898574.xml · nonDerivative · entry 1

MARCUS JOEL S · CIK 0001216955 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 351,354